Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus

Journal of Viral Hepatitis

Volumn 16, Issue 3, 2009, Pages 203-213

  Poynard, T ^a,b   Ngo, Y ^b   Marcellin, P ^c   Hadziyannis, S ^d   Ratziu, V ^b   Benhamou, Y ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BEAUJON HOSPITAL   (France)

^d Henri Dunant Hospital   (Greece)

Author keywords

ActiTest; Adefovir; Fibrosis; FibroSURE; FibroTest; Hepatitis B; Liver biopsy; Paired biopsies; Placebo; Serum markers

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HEPATITIS B(E) ANTIGEN; PLACEBO; VIRUS DNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REAGENT KITS, DIAGNOSTIC; TREATMENT OUTCOME;

EID: 60349099442     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01065.x     Document Type: Article

References (47)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003 362 : 2089 2094.
2. Valla C, The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol 2003 39 : 533 540.
3. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003 38 : S90 S103.
4. Sebastiani G, Alberti A. Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006 12 : 3682 3694.
5. Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986 8480 : 523 525.
6. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97 : 2614 2618.
7. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003 39 : 239 244.
8. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 1457.
9. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994 20 : 15 20.
10. Ter Borg F, Ten Kate FJ, Cuypers HT et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet 1998 351 : 1914 1918.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 1075.
12. Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004 3 : 8.
13. La Haute Autorité de Santé (HAS) in France. The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. Available at: http://www.has-sante.fr/portail/display.jsp?id=c- 476486 (accessed August 2008).
14. Naveau S, Raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD). Clin Gastroenterol Hepatol 2005 3 : 167 174.
15. Ratziu V, Massard J, Charlotte F et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006 6 : 6.
16. Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003 39 : 222 230.
17. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005 100 : 1970 1980.
18. Cales P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005 42 : 1373 1381.
19. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 348 : 808 816.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 348 : 800 807.
21. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004 50 : 1344 1355.
22. Ngo Y, Munteanu M, Messous D et al. A prospective analysis of prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006 52 : 1887 1896.
23. Imbert-Bismut F, Messous D, Thibaut V et al. Intralaboratory analytical variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004 42 : 323 333.
24. Messous D, Munteanu M, Morra R et al. Time impact of serum storage temperature on stability of important liver enzymes and proteins, and on FibroTest-ActiTest results. Clin Chim Acta 2005 335 : 400 (Abstract).
25. Knodell KG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 435.
26. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 699.
27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 293.
28. Hintze JL. NCSS 97 User Guide. Kaysville, UT : Number Cruncher Statistical Systems, 1997.
29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 : 837 845.
30. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York, NY : John Wiley & Sons Inc, 2002.
31. Poynard T, Halfon P, Castera L et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007 53 : 1615 1622.
32. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007 13 : 525 531.
33. Zhao LR, Xu DJ, Lu ZH, Zhao H, Lang ZW, Wang GQ. Validation of FibroTest to diagnose liver fibrosis to patients with chronic hepatitis B. Chin J Pract Intern Med 2007 27 : 1274 1277.
34. Castera L, Foucher J, Bernard PH et al. Prospective comparison in Fibroscan and FibroTest in inactive hepatitis B carriers. J Hepatol. 2006 44 : S169 (abstract).
35. Hilleret MN, Faure P, Trocme C et al. Diagnostic accuracy of MP3 score compared to Hyaluronate and FibroTest for evaluating liver fibrosis in chronic hepatitis B. J Hepatol. 2006 44 : S172 (abstract).
36. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 : 343 350.
37. Halfon P, Bourliere M, Deydier R et al. Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastroenterol 2006 101 : 547 555.
38. Montazeri G, Estakhri A, Mohamadnejad M et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005 5 : 32.
39. Mohamadnejad M, Montazeri G, Fazlollahi A et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006 101 : 2537 2545.
40. Park SY, Kang KH, Park JH et al. [Clinical efficacy of AST/ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis]. Korean J Gastroenterol 2004 43 : 246 251.
41. Schmilovitz-Weiss H, Tovar A, Halpern M et al. Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2006 13 : 671 677.
42. Ngo Y, Benhamou Y, Thibault V et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibrotest-Actitest) and viral load. PloS ONE 2008 3 : e2573.
43. Poynard T, Morra R, Halfon P et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterol 2007 7 : 40.
44. Poynard T, Imbert-Bismut F, Ratziu V et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002 9 : 128 133.
45. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003 38 : 481 492.
46. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2008 (in press).
47. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007 46 : 528 529.